Indonesia Lung Cancer Therapeutics Market Report 2022 to 2030

Indonesia Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Indonesia Lung Cancer Therapeutics Market will reach a value of $334 Mn from $179 Mn in 2022, growing at a CAGR of 8.1% during 2022-2030. The Lung Cancer Therapeutics Market in Indonesia is dominated by a few domestic pharmaceutical companies such as Dexa Medica, Kalbe Farma, and Phapros. The Lung Cancer Therapeutics Market in Indonesia is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Indonesia lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10IDPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Dr. Vishwa Modhia

Buy Now

Indonesia Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Indonesia Lung Cancer Therapeutics market will reach a value of $334 Mn from $179 Mn in 2022, growing at a CAGR of 8.1% during 2022-2030.

Indonesia is a lower middle-income, developing country located in Southeastern Asia between the Indonesian Ocean and the Pacific Ocean. Overall, the most common cancers in Indonesia are lung (11.58 %), breast (11.55 %), and colorectum (10.23 %), with the highest fatality rates in the lung (18.43 %), liver and bile duct (9.91 %), and stomach (10.23 %) (8.19 %). According to the most recent data, lung cancer is the third leading cause of mortality in women. It is the leading cause of death in males, surpassing colorectal and prostate cancer.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Indonesia reached 28,633 or 1.69% of total deaths. The age-adjusted Death Rate is 12.46 per 100,000 population ranks Indonesia 93^rd in the world. Indonesia's government spends 3.4% of its GDP on healthcare.

Indonesia Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Surgery, radiation therapy, chemotherapy, target therapy, and immunotherapy can all be used; however, the type of target therapy and immunotherapy treatment must be done specifically, namely biomolecular markers. Aside from a few patients treated at private facilities or travelling overseas, patients with cancer in Indonesia are finally directed to both Dharmais National Cancer Center and Cipto Mangunkusumo Hospital, both of which are governmental hospitals. When doing business in Indonesia, low labour costs and a demographic dividend provide a competitive edge. Business Process Outsourcing (BPO) is becoming more popular in Indonesia. These aspects could boost Indonesia's Lung Cancer Therapeutics market.

Market Restraints

Although lung cancer screening is not generally available in Indonesia, efforts are being undertaken to raise awareness and access to screening programmes. Indonesia is sensitive to shifts in Chinese demand, as well as persistent corruption and a lack of transparency. These factors may deter new entrants into the Indonesia Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Kalbe Farma: Kalbe Farma is an Indonesian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Dexa Medica: Dexa Medica is an Indonesian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Tempo Scan Pacific: Tempo Scan Pacific is an Indonesian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Phapros: Phapros is an Indonesian pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Kimia Farma: Kimia Farma is an Indonesian state-owned pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer

Recent Notable Updates

December 2022: Kalbe announced the completion of a Share Purchase Agreement between Sanofi Aventis Participations, Hoechst GmbH, and Usaha Minidin Raya, referred to collectively as the Sellers, and Kalbe and its subsidiary as the Buyers. With the fulfilment of the Share Purchase Agreement conditions, Kalbe Farma now has complete control of Aventis Pharma.

Healthcare Policies and Reimbursement Scenarios

The National Agency of Drug and Food Control (BPOM) and the Social Security Agency for Health regulate the regulation and payment of lung cancer therapies in Indonesia (BPJS Kesehatan). The BPJS Kesehatan, which runs the national health insurance programme, offers coverage for lung cancer therapies in the Indonesian healthcare system. Lung cancer therapies must be listed in the National Formulary (Formularium Nasional) and the List of Essential Medicines (Daftar Obat Esensial Nasional) to be eligible for reimbursement, which are lists of drugs and medicines certified for reimbursement by the BPJS Kesehatan.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.